Toronto, Canada – Dexcom, Inc. (NASDAQ: DXCM), a provider of real-time continuous glucose monitoring (rtCGM) for individuals with diabetes, has announced that Health Canada has granted approval for the next-generation Dexcom G7 Continuous Glucose Monitoring System. This revolutionary system, designed for individuals aged two years and older with all types of diabetes, is set to transform diabetes management in Canada with its unparalleled accuracy and advanced features.
Diabetes is a complex condition that affects over 3 million Canadians, necessitating constant monitoring of glucose levels and daily treatment decisions to effectively manage the disease. The approval of Dexcom G7 by Health Canada gives Canadians access to a groundbreaking technology that simplifies diabetes management and has been shown to reduce hospitalizations and emergency room visits due to hypoglycemia by up to 42 percent.
André Côté, Vice President and General Manager of Dexcom Canada, expressed excitement about the approval, stating, “For more than two decades, Dexcom has focused on sensor technology, continuously evolving our CGM systems by listening to the needs of people with diabetes and their caregivers. With our latest advancements in sensor technology and software integrations, we are entering a new era of diabetes care with continuous glucose monitoring at the core. Dexcom G7 builds upon the innovation of our previous CGM systems, offering greater accuracy, a simplified user experience, proven results, and extensive digital connectivity. Our next-generation Dexcom G7 will improve the quality of life and outcomes for people with diabetes, and we are thrilled to bring it to Canada by the end of 2023.”
The Dexcom G7 introduces a powerful and user-friendly approach to help individuals gain better control of their diabetes, enabling them to manage the disease with greater confidence. The system features a low-profile, all-in-one sensor and transmitter that warms up two times faster than any other CGM available. It provides real-time glucose readings, automatically transmitted to a compatible smart device or receiver, eliminating the need for routine finger pricks or scanning. With customizable alerts, the Dexcom G7 can warn of high or low glucose levels, including a predictive urgent low alert to help avoid dangerous hypoglycemic events. Users can easily share information with their family, loved ones, and healthcare teams through remote monitoring and reporting capabilities.
Dr. Alice Cheng, an Endocrinologist at Trillium Health Partners, Credit Valley Hospital, and St. Michael’s Hospital (Unity Health Toronto), highlighted the significance of real-time continuous glucose monitoring in diabetes care. She stated, “Real-time continuous glucose monitoring (rtCGM) has become the standard of care for many people living with diabetes, with clinical evidence supporting its effectiveness in reducing A1C levels, increasing time spent in the target glucose range, and reducing the number of low glucose events. With the approval of Dexcom G7, patients will have a new, simple-to-start and easy-to-use tool in their diabetes management toolbox to effectively control their diabetes and make informed health decisions based on reliable data and proven results.”
The Dexcom G7 boasts several enhancements and new features, including the smallest Dexcom sensor ever, which is 60 percent smaller than the Dexcom G6. The system offers multiple approved wear locations, providing greater comfort and discretion for users. It incorporates an all-in-one sensor and transmitter, streamlining the entire CGM system and user experience. With a 30-minute warm-up time, it has the fastest warm-up period among CGMs on the market, ensuring a quick and hassle-free start. Additionally, the Dexcom G7 allows for a 12-hour grace period to replace finished sensors, allowing for seamless transitions between sessions and providing users with more convenience and flexibility. The system also offers improved alert customization to meet individual user needs and preferences, and it comes with a redesigned and simplified mobile app integrated with Dexcom Clarity.
As the most connected CGM brand globally, Dexcom is actively collaborating with its insulin pump partners to integrate the Dexcom G7 into current and future automated insulin delivery systems, further enhancing diabetes management capabilities.
The approval of Dexcom G7 by Health Canada signifies a major milestone in diabetes care, granting Canadians access to an innovative technology that simplifies glucose monitoring, improves health outcomes, and enhances the quality of life for individuals living with diabetes. With its launch expected by the end of 2023, Dexcom G7 is set to revolutionize diabetes management in Canada and empower individuals to live healthier and more active lives.
